19.02.2015

Research Article: A Clinical Decision Support System for the Diagnosis, Fracture Risks and Treatment of Osteoporosis

Expanding medical knowledge increases the potential risk of medical errors in clinical practice. We present, the Osteoporosis Advisor (OPAD), a clinical decision support system in the field of the medical care of osteoporosis. We utilize clinical information from international guidelines and experts in the field of osteoporosis. Physicians are provided with user interface to insert standard patient data, from which OPAD provides instant diagnostic comments, 10-year risk of fragility fracture, treatment options for the given case, and when to offer a follow-up DXA-evaluation. Thus, the medical decision making is standardized according to the best expert knowledge at any given time. OPAD was evaluated in a set of 308 randomly selected individuals. OPAD’s ten year fracture risk computation is nearly identical to FRAX (r = 0.988). In 58% of cases OPAD recommended DXA evaluation at the present time. Following a DXA measurement in all individuals, 71% of those that were recommended to have DXA at the present time received recommendation for further investigation or specific treatment by the OPAD. In only 5.9% of individuals in which DXA was not recommended, the result of the BMD measurement changed the recommendations given by OPAD.

More ...
10.09.2014

Expeda and Dr. Bjorn R. Ludviksson discussing Autoimmune research and the use of CDSS in medical research

The Web news media portal HEILSUTORG discusses with Dr. Bjorn R. Ludviksson and Expeda the use of CDSS in Autoimmune medical research.

More ...
19.08.2014

Bloomberg Businessweek on Expeda

Bloomberg Businessweek on Expeda

More ...
16.08.2014

Expeda in the news

Expeda in the news

More ...
15.07.2014

Expeda Streamlining Osteoporosis Management Decisions

The following article was published by Value based Rheumatology (http://www.valuebasedrheumatology.com ) in their April 2014 issue.

More ...
16.05.2014

Expeda announces distribution agreement with Funnel Factory

Expeda and Funnel Factory ( www.funnelfactory.nl ) have entered into a sales and distribution agreement for the following markets: Belgium, Germany, Holland and Luxembourg. About Funnel Factory: The company provides services that help organizations to grow their revenues and lower operating costs by supporting sales that helps their customers to achieve their objectives in a more effective and efficient manner.

More ...
14.01.2014

Expeda collaborates with the Directorate of Health in Iceland

Expeda CDSS solution integrated with the Icelandic EMR / EPR system SAGA giving 95% of Icelandic healthcare professionals access to best possible expert medical advice.

More ...
25.11.2013

Expeda Osteoporosis Adviser presented on the World Congress on Controversies, Debates and Consensus in Bone, Muscle and Joint Diseases (BMJD) in Brussels, Belgium.

The fields of bone, muscle & joint diseases has undergone enormous expansion in clinical and basic data, as well as that of field-related technology.

More ...
02.07.2012

CE Declaration of Conformity

Today the Expeda Osteoporosis Adviser received it´s CE certification and is now fully compliant with relevant EU regulations.

More ...
22.05.2012

Osteoporosis Adviser App for the general public and non-professionals on iTunes and Google Play

The Expeda Osteoporosis Adviser is an easy to use tool providing individuals and non-professionals with valuable health information on Osteoporosis.

More ...
21.03.2012

Expeda Osteoporosis Adviser C-DSS in the global market

After years of development, rigorous testing and clinical trials, Expeda announced today the company will in March 2012, introduce to the global audience it´s Osteoporosis Adviser Clinical Decision Support System (CDSS).

More ...
01.11.2011

New investor joins Expeda

The Icelandic Venture Capital Fund invests in Expeda. Icelandic Venture Capital Fund is the leading Icelandic venture capital investor.

More ...
05.09.2011

Presidential Reward nomination

Presented by the President of Iceland

More ...
14.12.2010

Expeda Quality Assurance

Expeda receives certification of approval

More ...
01.12.2010

Expeda Osteoporosis Adviser interfaces with the SAGA EMR System

Using dot.net technology the Expeda Osteoporosis Adviser interfaces with the SAGA EMR system

More ...
01.11.2010

The Expeda DSS launched

Included in the new version are 1600 new cases and over 100 new sets of rules

More ...
01.11.2010

Expeda selected as a collaborator

Expeda becomes a collaborator in a study looking at the predictability of autoimmune disease markers for Rheumatoid arthritis.

More ...
01.10.2010

Expert Medical Opinion leaders join Expeda

The Expeda international advisory board strengthened

More ...
01.09.2010

Clinical testing of the Expeda Osteoporosis Adviser C-DSS

Clinical testing of the Osteoporosis Adviser C-DSS

More ...
02.08.2010

Expeda Rheumatology Adviser

Prototype of the Rheumatology Adviser was launched to day

More ...
01.06.2010

Expeda selected as a collaborator

Expeda selected as a collaborator in a study looking at the predictability of autoimmune disease markers

More ...
03.05.2010

Regional Medical Center in Gardabaer joins Expeda customers using the Osteoporosis Adviser C-DSS

The Regional Medical Center in Gardabaer joins Expeda customers using the Osteoporosis Adviser C-DSS

More ...